Anaphylaxis to Patent Blue Dye – Misadventure or Misdemeanour?

Moneret-Vautrin D.A. , Feldmann L. , Kanny G. , Baumann A. , Roland J. , Pere P. Incidence and risk factors for latent sensitization to chymopapain: predictive skin-prick tests in 700 candidates for chemonucleolysis. Clin Exp Allergy 1994; 24: 471–476.

Howard J. , Moo V. , Sivalinham P. Anaphylaxis and other adverse reactions to blue dyes: a case series. Anaesth Intensive Care 2011; 39: 287–292.

Kalimo K. , Jansen C.T. , Kormano M. Sensitivity to Patent Blue dye during skin-prick testing and lymphography. A retrospective and prospective study. Radiology 1981; 141: 365–367.

Gill G. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 2009; 16: 266–275.

Patent blue V and anaphylaxis. Australian Adverse Drug Reactions Bulletin 2002; 21: 10.

Aberer W. , Bircher A. , Romano A. , Blanca M. , Campi P. , Fernandez J. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58: 854–863.

Barthelmes L. , Goyal A. , Sudheer P. , Mansel R.E. Investigation of anaphylactic reaction after patent blue V dye injection. Breast 2010; 19: 516–520.

Haque R.A. , Wagner A. , Whisken J.A. , Nasser S.M. , Ewan P.W. Anaphylaxis to patent blue V: a case series and proposed diagnostic protocol. Allergy 2010; 65: 396–400.

Ingram D. , Hewett L. , Maddern P. Anaphylaxis to patent blue during sentinel lymph node biopsy. ANZ J Surg 2004; 74: 607–608.